S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
NASDAQ:ARCT

Arcturus Therapeutics (ARCT) Stock Price, News & Analysis

$25.98
-0.34 (-1.29%)
(As of 04/19/2024 ET)
Today's Range
$25.57
$26.88
50-Day Range
$25.98
$42.99
52-Week Range
$17.52
$43.81
Volume
626,328 shs
Average Volume
516,468 shs
Market Capitalization
$699.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$61.33

Arcturus Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
136.1% Upside
$61.33 Price Target
Short Interest
Bearish
19.60% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.81mentions of Arcturus Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$910,434 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.42) to $5.10 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.91 out of 5 stars

Medical Sector

579th out of 907 stocks

Pharmaceutical Preparations Industry

260th out of 424 stocks

ARCT stock logo

About Arcturus Therapeutics Stock (NASDAQ:ARCT)

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

ARCT Stock Price History

ARCT Stock News Headlines

Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Arcturus Therapeutics Holdings, Inc.
Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
ARCT Apr 2024 30.000 call
The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts
Recap: Arcturus Therapeutics Q4 Earnings
ARCT Sep 2024 30.000 put
Earnings Preview: Arcturus Therapeutics
See More Headlines
Receive ARCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
4/21/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ARCT
Fax
N/A
Employees
180
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$61.33
High Stock Price Target
$90.00
Low Stock Price Target
$45.00
Potential Upside/Downside
+136.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-29,730,000.00
Pretax Margin
-16.72%

Debt

Sales & Book Value

Annual Sales
$169.93 million
Book Value
$10.42 per share

Miscellaneous

Free Float
23,201,000
Market Cap
$699.38 million
Optionable
Optionable
Beta
2.60
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Joseph E. Payne M.Sc. (Age 52)
    Founder, President, CEO & Director
    Comp: $1.13M
  • Dr. Padmanabh Chivukula Ph.D. (Age 45)
    Founder, Chief Scientific Officer, COO & Secretary
    Comp: $787.5k
  • Mr. Andrew H. Sassine MBA (Age 60)
    CFO & Director
    Comp: $826.88k
  • Ms. Neda Safarzadeh
    Vice President and Head of IR/PR & Marketing
  • Mr. Lance Kurata
    Chief Legal Officer
  • Ms. Natash O. Bowman
    Chief Human Resources Officer
  • Mr. Kevin T. Skol
    Chief Business Officer
  • Dr. Juergen Froehlich FCPh (Age 68)
    M.D., MBA, Chief Medical Officer
  • Dr. Igor Smolenov M.D.
    Ph.D., Chief Development Officer
  • Joseph Roberts
    Controller

ARCT Stock Analysis - Frequently Asked Questions

Should I buy or sell Arcturus Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARCT shares.
View ARCT analyst ratings
or view top-rated stocks.

What is Arcturus Therapeutics' stock price target for 2024?

7 equities research analysts have issued 1 year price targets for Arcturus Therapeutics' stock. Their ARCT share price targets range from $45.00 to $90.00. On average, they anticipate the company's share price to reach $61.33 in the next year. This suggests a possible upside of 136.1% from the stock's current price.
View analysts price targets for ARCT
or view top-rated stocks among Wall Street analysts.

How have ARCT shares performed in 2024?

Arcturus Therapeutics' stock was trading at $31.53 on January 1st, 2024. Since then, ARCT shares have decreased by 17.6% and is now trading at $25.98.
View the best growth stocks for 2024 here
.

Are investors shorting Arcturus Therapeutics?

Arcturus Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 4,810,000 shares, an increase of 14.3% from the March 15th total of 4,210,000 shares. Based on an average daily trading volume, of 454,500 shares, the days-to-cover ratio is currently 10.6 days. Currently, 19.6% of the shares of the company are short sold.
View Arcturus Therapeutics' Short Interest
.

When is Arcturus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ARCT earnings forecast
.

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) issued its quarterly earnings data on Thursday, March, 7th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.69) by $1.37. The biotechnology company had revenue of $33.99 million for the quarter, compared to the consensus estimate of $64.14 million. Arcturus Therapeutics had a negative net margin of 15.65% and a negative trailing twelve-month return on equity of 18.22%.

What is Joe Payne's approval rating as Arcturus Therapeutics' CEO?

11 employees have rated Arcturus Therapeutics Chief Executive Officer Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among the company's employees. 70.0% of employees surveyed would recommend working at Arcturus Therapeutics to a friend.

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and

Who are Arcturus Therapeutics' major shareholders?

Arcturus Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (4.74%), Hennion & Walsh Asset Management Inc. (0.12%), Allspring Global Investments Holdings LLC (0.11%) and Denali Advisors LLC (0.02%). Insiders that own company stock include Keith C Kummerfeld, Magda Marquet, Pad Chivukula and Ultragenyx Pharmaceutical Inc.
View institutional ownership trends
.

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARCT) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners